## 3 Results  
### Study Population  
In total, there were 35,581 patients in the MDV database with a new diagnosis of MM between 1 January 2016 and 31 October 2023, of whom 682 started 1L therapy within 365 days of MM diagnosis. Baseline and demographic data were available at the time of MM diagnosis for 344 patients (Figure A3). Of these patients, 208 (60.5%) received DRd as 1L, 78 (22.7%) as 2L, and 58 (16.9%) as \(\geq\)3L (Table 1). The median (range) age was 76 (51-92) years in the overall population and was similar across treatment-line groups. The median time from MM diagnosis to DRd administration was 47 days overall, and was 20 (range 0-354), 217 (16-1520), and 452 (64-2211) days in patients who received DRd as 1L, 2L, and \(\geq\)3L, respectively. The CCI score was categorized as 'low' (score of 0) or'medium' (score of 1 or 2) in 79 (38.0%) and 86 (41.3%) patients, respectively, in the 1L group, 24 (30.8%) and 37 (47.4%) patients in the 2L group, and 21 (36.2%) and 22 (37.9%) patients in the \(\geq\)3L group.  
\begin{table}
\begin{tabular}{c c c c} \hline \hline
**Parameter** & **1L DRd** & **2L DRd** & \(\geq\)**3L DRd** \\  & \(n\) = **208** & \(n\) = **78** & \(n\) = **58** \\ \hline Sex, \(n\) (\%) & & & \\ Male & 103 (49.5) & 45 (57.7) & 33 (56.9) \\ Female & 105 (50.5) & 33 (42.3) & 25 (43.1) \\ Age, median (range), years & 76 (51–90) & 75 (52–92) & 73 (51–92) \\ CCI category, \(n\) (\%) & & & \\ Low (score 0) & 79 (38.0) & 24 (30.8) & 21 (36.2) \\ Medium (score 1 or 2) & 86 (41.3) & 37 (47.4) & 22 (37.9) \\ High (score 3 or 4) & 35 (16.8) & 15 (19.2) & 15 (25.9) \\ Very high (score \(\geq\) 5) & 8 (3.8) & 2 (2.6) & 0 \\ Time from diagnosis to DRd initiation, & 20 (0–354) & 217 (16–1520) & 452 (64–2211) \\ median (range), days & 22.8 \(\pm\) 4.2 & 23.5 \(\pm\) 3.4 & 23.2 \(\pm\) 3.1 \\ BMI, mean \(\pm\) SD, kg/m\({}^{2}\) & 22.8 \(\pm\) 4.2 & 23.5 \(\pm\) 3.4 & 23.2 \(\pm\) 3.1 \\ Comorbidities, \(n\) (\%) & & & \\ Congestive heart failure & 40 (19.2) & 17 (21.8) & 13 (22.4) \\ Renal disease & 38 (18.3) & 13 (16.7) & 7 (12.1) \\ Diabetes & 31 (14.9) & 13 (16.7) & 8 (13.8) \\ Without chronic complications & 25 (12.0) & 10 (12.8) & 6 (10.3) \\ With chronic complications & 6 (2.9) & 3 (3.8) & 2 (3.4) \\ Cererovascular disease & 29 (13.9) & 6 (7.7) & 10 (17.2) \\ Liver disease & 25 (12.5) & 10 (12.8) & 6 (10.3) \\ Mild & 24 (11.5) & 10 (12.8) & 6 (10.3) \\ Moderate or severe & 1 (0.5) & 0 & 0 \\ Chronic pulmonary disease & 20 (9.6) & 9 (11.5) & 2 (3.4) \\ Peptic ulcer disease & 18 (8.7) & 16 (20.5) & 15 (25.9) \\ Peripheral vascular disease & 12 (5.8) & 5 (6.4) & 4 (6.9) \\ Rheumatic disease & 7 (3.4) & 5 (6.4) & 2 (3.4) \\ Myocardial infarction & 5 (2.4) & 2 (2.6) & 2 (3.4) \\ Dementia & 2 (1.0) & 2 (2.6) & 1 (1.7) \\ Hemiplegia or paraplegia & 2 (1.0) & 0 & 0 \\ AIDS/HIV infection & 1 (0.5) & 0 & 0 \\ \hline \hline \end{tabular}  
* 1L, first line; 2L, second line; \(\geq\)3L, third line or later; AIDS, autoimmune deficiency syndrome; BMI, body mass index; CCI, Charlson Comorbidity Index; DRd, daratumumab + lenalidomide + dexamethasone; HIV, human ununodeficiency virus; SD, standard deviation.  
\end{table}
Table 1: Patient baseline characteristics at the time of multiple myeloma diagnosis, stratified by daratumumab + lenalidomide + dexamethasone treatment line (_N_ = 344).  
In total, baseline and demographic data were available at the time of the first DRd administration for 323 patients (Table 2). Of these, 200 patients (61.9%) received 1L DRd, 72 (22.3%) received 2L DRd, and 51 (15.8%) received \(\geq\)3L DRd. The baseline and demographic characteristics of these patients were consistent with those of the overall population.